PET-CT with Gallium 68(PSMA) Doctors Abroad — Page 3

Dr. Hasan Mutlu is a medical oncologist at Medical Park Antalya Hospital Complex. He specializes in immunotherapy, targeted cancer therapies, and genetic research in cancer treatment. Dr. Mutlu received his medical degree from Hacettepe University. He holds the title of Professor of Medicine. Dr. Mutlu focuses on organ tumor diagnosis and chemotherapy.

• Specializes in both medical and pediatric oncology cases.
• Treats complex conditions including neuroblastoma, Wilms tumor, and Ewing's sarcoma.
• Performs biological therapies and stays active in next-generation genetic research.
• Works at the Mediterranean region’s largest private hospital with PET-CT and LINAC technology.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Dr. Ercan Ozden is a medical oncologist and internal medicine specialist at VM Medical Park Pendik. He provides treatment for a wide range of cancers, including breast, lung, and colon cancer. Dr. Ozden trained at Istanbul University, Cerrahpasa Faculty of Medicine. He later completed a medical oncology subspecialty at Kocaeli University.

• Specializes in immunotherapy, target therapy, and chemotherapy for complex cases.
• Treats patients at a JCI-accredited hospital in Istanbul.
• Performs staging and biopsies for liver, lung, and pancreatic tumors.
• Provides targeted immunotherapy using medications like Keytruda.

Dr. Zohar Dotan heads the urology department at Sheba Medical Center. He specializes in treating prostate and kidney cancers using PET-CT with Gallium 68(PSMA) for precise staging.

• Fellowship-trained in uro-oncology at Memorial Sloan Kettering Cancer Center in New York
• President of the Israeli Uro-Oncology Society
• Recipient of prestigious awards from the American Association of Clinical Surgery
• Author of 50+ scientific publications on urological cancer research
• Member of the American and European Associations of Urology

Prof. Gil Raviv is a specialist in andrology and reconstructive urology at Sheba Medical Center. Forbes named him among the Best Doctors in Israel. He is the director of the Andrology Unit. Dr. Raviv focuses on male infertility, sexual health, and urethral reconstruction. He works at Sheba, a Top 10 world-ranked hospital.

• Performs specialized sperm retrieval techniques including micro-TESE, TESA, and MESA.
• Treats complex conditions like erectile dysfunction, Peyronie’s disease, and azoospermia.
• Uses microsurgical methods and robotic systems for prostate and urological procedures.
• Provides stem cell therapy and shockwave treatment for sexual dysfunction.

Dr. Dorit Zilberman is a senior urologist at Sheba Medical Center in Israel. She is a pioneer of robotic and minimally invasive urologic surgery. Dr. Zilberman treats kidney, bladder, and prostate cancers. She helped launch the da Vinci robotic surgery program at Sheba. Forbes Israel recognized her among the nation's best doctors.

• Authored over 160 scientific publications in urologic oncology and endourology.
• Completed fellowship training at Duke University Medical Center in the US.
• Performs robotic prostatectomy, laser lithotripsy, and kidney-sparing surgery.
• Member of the American and European Urological Associations and the Endourological Society.

Dr. Yaacov Lawrence is the Chair of Radiation Oncology at Sheba Medical Center. He specializes in precision radiation therapy and neuro-oncology. Dr. Lawrence pioneered celiac plexus radiosurgery for pancreatic cancer pain management. He holds the FASTRO designation, one of the highest honors in his specialty.

• Leads the Gastrointestinal Cancer Program at Sheba Medical Center.
• Performs stereotactic radiosurgery for brain tumors and nervous system cancers.
• Authored over 280 scientific publications on personalized radiation protocols.
• Completed radiation oncology fellowship training at Thomas Jefferson University.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Eytan Aharon Ben-Ami leads the Oncology Division at Sheba Medical Center in Israel. He specialized in sarcoma and bone oncology at the Dana-Farber Cancer Institute. Dr. Ben-Ami founded the Sheba Clinical Research Organization to advance cancer studies. He treats rare bone tumors and soft tissue sarcomas with personalized protocols.

• Heads the Early-Phase Clinical Trials Unit for innovative cancer therapies.
• Authored over 40 scientific publications on molecular mechanisms and early detection.
• Leads Phase I trials in targeted therapy and immunotherapy for rare cancers.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Cem Basatac is an associate professor and urologist at Gayrettepe Florence Nightingale Hospital in Istanbul. He specializes in laparoscopic and robotic urological surgery. Dr. Basatac provides treatment for complex conditions like kidney cysts, varicocele, and prostate disease. He works at a JCI-accredited facility that treats 200,000 patients annually.

• Performs robotic da Vinci prostatectomies and nephrectomies for kidney conditions.
• Uses HoLEP and GreenLight laser techniques for prostatic hyperplasia treatment.
• Specializes in microsurgical and embolization procedures for varicocele.
• Treats infertility related conditions including azoospermia and testicular tumors.

The doctor is an experienced specialist in interventional radiology, with a dedicated clinical focus on thyroid and prostate imaging and interventions. With a strong academic foundation from Istanbul University Cerrahpaşa Faculty of Medicine and specialized residency training in radiology at S.B. Haydarpaşa Numune Training and Research Hospital, the doctor brings extensive expertise to the field.

Throughout a distinguished career, the doctor has contributed to clinical practice at institutions including Başkent University Istanbul Hospital and S.B. Haydarpaşa Numune Training and Research Hospital. Additionally, the doctor holds a background in healthcare management from Anadolu University and maintains active professional memberships with the Istanbul Medical Chamber and the Istanbul Radiology Society.

Dr. Daniel Leszczynski is a urologist at Carolina Hospital in Warsaw. He specializes in laparoscopic radical prostatectomy and urinary incontinence surgery. He developed a unique CO2 laser technique for the treatment of phimosis. Dr. Leszczynski is a Fellow of the European Board of Urology. He co-leads surgical workshops on incontinence treatment for other medical professionals.

• Performs laser and surgical phimosis removal and foreskin reconstruction.
• Treats urinary incontinence using stem cell therapy and medication.
• Manages conditions like varicocele, hydrocele, and prostate hyperplasia.
• Fluent in English, German, Russian, and Polish.

Dr. Zulfu Sertkaya is an associate professor and andrologist at Andro Expertise in Istanbul. He holds the FEBU title from the European Association of Urology. Dr. Sertkaya focuses on male health, sexual function, and aesthetic urological procedures. He treats patients at his clinic and performs surgeries at affiliated hospitals.

• Earned Fellow of the European Board of Urology (FEBU) status.
• Specialize in andrology, male sexual health, and aesthetic urology.
• Performs penile implant surgery and varicocelectomy for infertility.
• Works at a clinic accredited by the Turkish Medical Association.

Dr. Stefan Czarniecki has performed over 2,500 prostate fusion biopsies. He is a urological surgeon at Carolina Hospital in Warsaw. Dr. Czarniecki runs Central Europe’s only comprehensive diagnostic and robotic prostate cancer center. He focuses on personalized diagnostics and oncological urology.

• Ranks among global leaders for prostate diagnostic procedures.
• Uses HIFU robotic therapy for prostate cancer treatment.
• Collaborates with clinical centers in the USA, Germany, and France.
• Sits on committees for the European Association of Urology.

The doctor is a highly experienced urology specialist with an extensive career spanning over three decades. After graduating from Uludağ University Faculty of Medicine in 1988, the doctor completed a specialization program in urology in 1997. The doctor attained the rank of Associate Professor in 2006 and achieved the title of Professor in 2011.

Throughout a distinguished career, the doctor has held numerous leadership roles, including serving as the Head of the Urology Department at multiple university hospitals and acting as an Education and Administrative Supervisor at major training and research hospitals. The doctor possesses deep expertise in clinical urology, having served in various state and private medical institutions across Turkey.

Dr. Nejat Akalan heads the Neurosurgery Department at Medipol Mega University Hospital in Istanbul. He specializes in epilepsy surgery and neuro-oncology for both children and adults. Dr. Akalan uses intraoperative MRI and the O-arm system to improve surgical accuracy. He has published over 110 scientific papers and co-authored a neurosurgery textbook.

• Performs brain tumor removals using minimally invasive techniques to speed recovery.
• Treats complex conditions like glioblastoma, glioma, and pituitary adenoma.
• Specializes in surgical treatment for epilepsy and movement disorders.
• Works at a JCI-accredited hospital serving over 1,200 patients daily.

Dr. Cevper Ersoz is a urologist at Medipol Acibadem District Hospital in Istanbul. He specializes in robotic and laparoscopic surgery for urological cancers. Dr. Ersoz is a Fellow of the European Board of Urology (FEBU). He completed an observership in urologic surgery at the University of Michigan, USA.

• Author of over 130 national and international peer-reviewed scientific publications.
• Treats benign prostate hyperplasia using HoLEP, TuLEP, and Rezum techniques.
• Performs minimally invasive procedures for stone diseases, including PCNL and URS.
• Practices at JCI-accredited Medipol Acibadem, which uses the da Vinci robotic system.

Professor Tamer Atasever is a leading nuclear medicine specialist at Medipol Mega University Hospital. He uses PET-CT with Gallium 68 (PSMA) to find prostate cancer cells with high precision.

• Former Director of Nuclear Medicine at Ankara Order Laboratory
• Member of the European Association of Nuclear Medicine (EANM)
• Achieved the rank of Professor at Gazi University
• Specializes in using radioactive isotopes to detect and treat complex tumors
• Expert in oncological imaging and targeted radiation therapies

Dr. Tuncay Tas is a urological surgeon at Safe Urology Clinic in Istanbul. He is among the first five experts globally to publish data on P-Shot applications. Dr. Tas specializes in urological oncology and male sexual health. He completed a fellowship in laparoscopic urology at Heidelberg University, Germany.

• Pioneered combined PRP and stem cell penile therapy in Turkey.
• Developed a certified surgical technique for penile circumference improvement.
• Performs robotic prostatectomies and kidney-sparing surgeries for cancer treatment.
• Serves as an instructor for the International Society for Stem Cells Applications.